
    
      To evaluate safety, effectiveness, pharmacokinetics and tolerance of ceftaroline fosamil in
      pediatric subjects ages 2 months to < 18 years who are initially hospitalized with
      Complicated Community Acquired Bacterial Pneumonia (CABP) at high risk of infection due to
      methicillin-resistant Staphylococcus aureus (MRSA)
    
  